1. Home
  2. ABLV vs GBIO Comparison

ABLV vs GBIO Comparison

Compare ABLV & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$0.74

Market Cap

39.5M

Sector

N/A

ML Signal

HOLD

Logo Generation Bio Co.

GBIO

Generation Bio Co.

HOLD

Current Price

$5.66

Market Cap

36.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
GBIO
Founded
2015
2016
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.5M
36.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ABLV
GBIO
Price
$0.74
$5.66
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$8.88
AVG Volume (30 Days)
19.6K
93.6K
Earning Date
09-30-2025
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$114,319,869.00
$15,270,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$3.00
52 Week High
$1.77
$9.25

Technical Indicators

Market Signals
Indicator
ABLV
GBIO
Relative Strength Index (RSI) 56.53 54.81
Support Level $0.65 $5.41
Resistance Level $0.77 $5.72
Average True Range (ATR) 0.07 0.13
MACD 0.01 0.01
Stochastic Oscillator 64.29 78.38

Price Performance

Historical Comparison
ABLV
GBIO

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: